Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC) patients, ...
Airs: Sundays and Mondays at 7 p.m. AEDT (4 a.m. EST) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback